SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: PharmaPoint: Hemophilia A and B - Argentina Drug Forecast and Market Analysis to 2022

[March 14, 2014]

Research and Markets: PharmaPoint: Hemophilia A and B - Argentina Drug Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/75tvqs/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Argentina Drug Forecast and Market Analysis to 2022" report to their offering.

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Argentina ranks fourth among pharmaceutical markets in Latin America. According to Our primary research, the majorit of Argentine hemophilia patients have access to recombinant FVIII and RIX products through private insurance plans or through the national social security program. However, the national insurance program only covers on-demand treatment and plasma-derived concentrates.


Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on the key drugs in Argentina including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for the top drugs in Argentina from 2012-2022.

- Analysis of the impact of key events as well the drivers and restraints affecting Argentina Hemophilia A and B market.

Reasons to Buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of drug performance

- Obtain sales forecast for drugs from 2012-2022 in Argentina

Key Topics Covered

1 Table of Contents

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Opportunity and Unmet Need

7 Pipeline Assessment

8 Market Outlook

9 Appendix

For more information visit http://www.researchandmarkets.com/research/75tvqs/pharmapoint

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy